{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:45:49Z","timestamp":1789577149555,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jns.2023.120851","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T15:18:16Z","timestamp":1699024696000},"page":"120851","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Impact of diabetes and glycated hemoglobin level on the clinical manifestations of Parkinson's disease"],"prefix":"10.1016","volume":"454","author":[{"given":"Keitaro","family":"Ogaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narihiro","family":"Nozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Shiina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Sakuramoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2023.120851_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"6","key":"10.1016\/j.jns.2023.120851_bb0010","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","article-title":"Epidemiology of Parkinson\u2019s disease","volume":"5","author":"de Lau","year":"2006","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.jns.2023.120851_bb0015","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/mds.27802","article-title":"Update of the MDS research criteria for prodromal Parkinson\u2019s disease","volume":"34","author":"Heinzel","year":"2019","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.jns.2023.120851_bb0020","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000338405","article-title":"Central dopaminergic activity influences metabolic parameters in healthy men","volume":"97","author":"Brunerova","year":"2013","journal-title":"Neuroendocrinology"},{"issue":"19","key":"10.1016\/j.jns.2023.120851_bb0025","doi-asserted-by":"crossref","first-page":"e1654","DOI":"10.1212\/WNL.0000000000005475","article-title":"Diabetes mellitus and Parkinson disease","volume":"90","author":"Pagano","year":"2018","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jns.2023.120851_bb0030","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/abbs\/gmz073","article-title":"High-fat diet causes increased endogenous neurotoxins and phenotype of Parkinson\u2019s disease in mice","volume":"51","author":"Wu","year":"2019","journal-title":"Acta Biochim. Biophys. Sin. Shanghai"},{"issue":"8","key":"10.1016\/j.jns.2023.120851_bb0035","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1002\/mds.29122","article-title":"The impact of type 2 diabetes in Parkinson\u2019s disease","volume":"37","author":"Athauda","year":"2022","journal-title":"Mov. Disord."},{"issue":"12","key":"10.1016\/j.jns.2023.120851_bb0040","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.jns.2023.120851_bb0045","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: onset, progression and mortality","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jns.2023.120851_bb0050","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1447-0594.2011.00772.x","article-title":"Evaluation of a Japanese version of the Mini-mental state examination in elderly persons","volume":"12","author":"Ideno","year":"2012","journal-title":"Geriatr Gerontol Int"},{"issue":"3","key":"10.1016\/j.jns.2023.120851_bb0055","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/mdc3.12921","article-title":"Levodopa equivalent dose conversion factors: an updated proposal including Opicapone and safinamide","volume":"7","author":"Schade","year":"2020","journal-title":"Mov. Disord. Clin. Pract."},{"issue":"4","key":"10.1016\/j.jns.2023.120851_bb0060","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/chemse\/bjj042","article-title":"Development of a smell identification test using a novel stick-type odor presentation kit","volume":"31","author":"Saito","year":"2006","journal-title":"Chem. Senses"},{"issue":"5","key":"10.1016\/j.jns.2023.120851_bb0065","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.sleep.2008.04.015","article-title":"Development of a Japanese version of the Epworth sleepiness scale (JESS) based on item response theory","volume":"10","author":"Takegami","year":"2009","journal-title":"Sleep Med."},{"issue":"1\u20132","key":"10.1016\/j.jns.2023.120851_bb0070","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jns.2012.03.022","article-title":"Nocturnal disturbances and restlessness in Parkinson\u2019s disease: using the Japanese version of the Parkinson\u2019s disease sleep scale-2","volume":"318","author":"Suzuki","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2023.120851_bb0075","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.clineuro.2014.07.007","article-title":"Reliability of the Japanese version of the scales for outcomes in Parkinson\u2019s disease-autonomic questionnaire","volume":"124","author":"Matsushima","year":"2014","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"11","key":"10.1016\/j.jns.2023.120851_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165869","article-title":"Usefulness of cardiac MIBG scintigraphy, olfactory testing and substantia Nigra Hyperechogenicity as additional diagnostic markers for distinguishing between Parkinson\u2019s disease and atypical parkinsonian syndromes","volume":"11","author":"Fujita","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jns.2023.120851_bb0085","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jns.2017.01.042","article-title":"Combined use of dopamine transporter imaging (DAT-SPECT) and (123)I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy for diagnosing Parkinson\u2019s disease","volume":"375","author":"Yoshii","year":"2017","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.jns.2023.120851_bb0090","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3233\/JPD-212725","article-title":"Diabetes mellitus and Parkinson\u2019s disease: a systematic review and Meta-analyses","volume":"11","author":"Komici","year":"2021","journal-title":"J. Parkinsons Dis."},{"issue":"1","key":"10.1016\/j.jns.2023.120851_bb0095","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s40478-021-01171-0","article-title":"Mixed pathologies in pancreatic \u03b2 cells from subjects with neurodegenerative diseases and their interaction with prion protein","volume":"9","author":"Martinez-Valbuena","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"issue":"3","key":"10.1016\/j.jns.2023.120851_bb0100","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3233\/JPD-191900","article-title":"The association between type 2 diabetes mellitus and Parkinson\u2019s disease","volume":"10","author":"Cheong","year":"2020","journal-title":"J. Parkinsons Dis."},{"issue":"3","key":"10.1016\/j.jns.2023.120851_bb0105","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3233\/JAD-190485","article-title":"Cardiovascular disease, diabetes mellitus, and hypertension in Lewy body disease: a comparison with other dementia disorders","volume":"71","author":"Javanshiri","year":"2019","journal-title":"J. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.jns.2023.120851_bb0110","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1212\/WNL.0b013e31827b1a07","article-title":"Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia","volume":"80","author":"Gomperts","year":"2013","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jns.2023.120851_bb0115","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13041-022-00964-1","article-title":"Beta amyloid deposition and cognitive decline in Parkinson\u2019s disease: a study of the PPMI cohort","volume":"15","author":"Mihaescu","year":"2022","journal-title":"Mol. Brain"},{"issue":"5","key":"10.1016\/j.jns.2023.120851_bb0120","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.neurobiolaging.2013.11.001","article-title":"Dysregulation of glucose metabolism is an early event in sporadic Parkinson\u2019s disease","volume":"35","author":"Dunn","year":"2014","journal-title":"Neurobiol. Aging"},{"issue":"6","key":"10.1016\/j.jns.2023.120851_bb0125","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/mds.28545","article-title":"Euglycemia indicates favorable motor outcome in Parkinson\u2019s disease","volume":"36","author":"Markaki","year":"2021","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.jns.2023.120851_bb0130","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/mds.28551","article-title":"Type 2 diabetes as a determinant of Parkinson\u2019s disease risk and progression","volume":"36","author":"Chohan","year":"2021","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.jns.2023.120851_bb0135","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/mds.29009","article-title":"Diabetes, glycated hemoglobin (HbA1c), and Neuroaxonal damage in Parkinson\u2019s disease (MARK-PD study)","volume":"37","author":"Uyar","year":"2022","journal-title":"Mov. Disord."},{"issue":"10","key":"10.1016\/j.jns.2023.120851_bb0140","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1093\/brain\/awaa262","article-title":"Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes","volume":"143","author":"Brauer","year":"2020","journal-title":"Brain"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X2300312X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X2300312X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T16:05:10Z","timestamp":1758384310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X2300312X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":28,"alternative-id":["S0022510X2300312X"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2023.120851","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of diabetes and glycated hemoglobin level on the clinical manifestations of Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2023.120851","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"120851"}}